We found that AD patients with clinical seizure history (AD+Sz) exhibited more severe tau pathological ratings (phosphorylated tau (Ser396/404); PHF1 antibody) compared to AD patients without a clinical seizure history (AD-Sz). The gene discussed is MAPT; the disease is Alzheimer disease.